Wegovy access in Saudi Arabia: the SFDA Personal Importation Program

How Saudi patients obtain authentic Wegovy (semaglutide injection 2.4 mg) for chronic weight management and cardiovascular risk reduction through SFDA's named-patient pathway.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Wegovy is the Novo Nordisk brand of semaglutide 2.4 mg once-weekly injection, approved by the US FDA for chronic weight management in adults with obesity or with overweight plus a weight-related comorbidity (June 2021), pediatric chronic weight management for patients 12 years and older (December 2022), and reduction of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and obesity or overweight (March 2024). It is the first weight-management drug ever to carry a cardiovascular indication. Wegovy is registered with the Saudi Food and Drug Authority (SFDA) and commercially available through SFDA-authorised channels, but supply has been constrained in the Kingdom throughout 2023 to 2025, and counterfeit semaglutide pens have surfaced in regional gray-market channels. For Saudi patients who want the authentic Novo Nordisk product on a documented chain of custody, the named-patient route through the SFDA Personal Importation Program (PIP) is the lawful alternative to regional gray-market sourcing.

Reserved for you.

Why Saudi families reach for Wegovy through NPP

Saudi Arabia is one of the strongest regional markets for Wegovy demand. The Kingdom carries one of the higher prevalence rates of adult obesity and type 2 diabetes in the Gulf, and Saudi Vision 2030's Health Sector Transformation Program has accelerated investment in metabolic and cardiovascular care. Wegovy is registered with SFDA, but registration has not translated to consistent on-shelf availability. Local pharmacies have routinely rationed by titration strength through the 2023 to 2025 supply ramp, and waitlists have been common, particularly for the maintenance 2.4 mg pen and the lower-dose starter pens that initiate therapy.

The harder problem is counterfeit and diverted product. WHO and multiple national regulators have issued repeated medical product alerts since 2023 about counterfeit semaglutide pens in MENA, Latin America, and parts of Asia. For a Saudi family paying out of pocket for chronic weight management, the calculus is not "Wegovy or no drug"; it is "authentic Wegovy on a documented supply chain, or a pen that may not be what the label says it is." The SFDA Personal Importation Program is the lawful pathway for a Saudi-licensed physician to import the authentic Novo Nordisk product for a named patient when local stocking cannot meet the clinical timeline. Reserve Meds sources only through US authorised distributors with DSCSA traceability and ships under validated cold-chain with continuous temperature logging. Chain-of-custody documentation accompanies every shipment.

The SFDA Personal Importation Program for Wegovy

The SFDA Personal Importation Program allows a Saudi-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority and a clinically equivalent locally registered alternative is not suitable or not available on the patient's clinical timeline. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector through the Ghad digital platform.

For Wegovy the clinical-justification angle pairs indication eligibility with the authenticity-and-continuity argument. A complete application typically includes:

- A clinical justification letter from the treating endocrinologist, internist, or cardiologist naming the on-label indication and documenting the eligibility criteria: adult patients with BMI of 30 kg/m² or higher (obesity), or BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia; pediatric patients 12 years and older with BMI at or above the 95th percentile for age and sex; or established cardiovascular disease with obesity or overweight (CV-risk indication)
- The treating physician's Saudi Commission for Health Specialties (SCFHS) license verification
- An anonymised patient identifier in SFDA's required format
- Product details: Wegovy (semaglutide injection 2.4 mg), the specific pen strength for the titration stage (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg maintenance), manufacturer Novo Nordisk, country of origin, pack size, quantity, lot, and expiry
- The destination dispensing facility license number for the SFDA-licensed pharmacy with validated refrigeration to receive and store the product
- A cold-chain plan from the US authorised distributor through international transit with continuous temperature monitoring and excursion logging, with explicit chain-of-custody documentation

Approval timelines for routine cases (registered drug, clear on-label indication, documented eligibility) typically run 10 to 21 business days. Cases requiring extra clinical context (pediatric eligibility, CV-risk indication with prior event documentation) can extend modestly. Authenticity and the chain-of-custody dossier are the differentiators relative to regional gray-market alternatives.

Where Wegovy gets dispensed in Saudi Arabia

Wegovy is a 2 to 8 degrees Celsius cold-chain biologic and must be stored under continuous refrigeration in the original carton. The dispensing footprint is the SFDA-licensed pharmacy network with validated refrigeration. Institutions that handle named-patient imports of injectable biologics as established practice include the endocrinology and metabolic-care services at King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh and Jeddah; King Abdulaziz Medical City (KAMC) and the Ministry of National Guard Health Affairs network (MNGHA); the cardiology and weight-management programs at Dr. Sulaiman Al Habib Medical Group (HMG) across Riyadh, Jeddah, and the Eastern Province; Saudi German Health endocrinology; Dr. Soliman Fakeeh Hospital in Jeddah; and Dallah Hospital in Riyadh. For private weight-management clinics in Riyadh and Jeddah without internal import infrastructure, the practical

route is partnering with an SFDA-licensed specialty importer that files the PIP and delivers under chain-of-custody to the prescribing clinic's affiliated dispensing pharmacy.

Once received, an unopened Wegovy pen is stable at room temperature up to 30 degrees Celsius for up to 28 days from first removal from refrigeration; the 28-day clock starts on first removal and does not reset. This gives families operational flexibility during the in-use period but consumes against any in-transit room-temperature exposure.

Real cost picture for Wegovy in Saudi Arabia

US wholesale acquisition cost for Wegovy is approximately USD 1,349 per 28-day pen, equating to roughly USD 16,000 to USD 17,600 per year at list. The Saudi riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD, so monthly US WAC translates to roughly SAR 5,060, with named-patient acquisition typically running modestly higher to cover authorised-distributor handling. The Reserve Meds firm quote is itemised: drug cost, international cold-chain logistics, SFDA permit handling, coordinator fee. Each line item is shown separately. Cash-pay-self-pay programs offered in the United States by Novo Nordisk (NovoCare Pharmacy at USD 349 per month, commercial-insurance copay programs) do not extend to international patients sourcing through a US named-patient pathway.

International cold-chain logistics for Wegovy typically runs USD 800 to USD 1,500 per shipment (approximately SAR 3,000 to SAR 5,600). Recurring quarterly fills are the realistic cadence for maintenance therapy, and the Reserve Meds coordinator helps families plan refill timing to avoid in-transit gaps. On the insurance side, Bupa Arabia, Tawuniya, and MedGulf Arabia each assess named-patient imports case by case; weight-management coverage varies meaningfully by plan, with some commercial plans excluding obesity therapies and others reimbursing partially when the patient meets BMI and comorbidity thresholds. Reserve Meds supplies the documentation; the claim remains with you or your hospital.

Typical timeline for Wegovy in Saudi Arabia

For a first-time Wegovy patient with a clear eligibility letter and a current prescription, the typical end-to-end cycle is 4 to 7 weeks for the starter-titration pen and approximately 4 to 6 weeks for subsequent refills once the institutional rails are in place. The SFDA PIP step generally runs 10 to 21 business days for routine cases. US-side sourcing through an authorised distributor adds approximately 1 to 2 weeks, and validated cold-chain transit with Saudi customs clearance typically adds 3 to 5 days. Pen strength is locked at firm-quote issuance because the titration stage determines which SKU is sourced. Timelines are presented as typical ranges, not promises.

What your physician needs to provide

The clinical justification letter for Wegovy is the centrepiece of the SFDA package. For this product the letter typically includes:

- The patient's measured BMI and weight-related comorbidities (for the obesity indication), or the established cardiovascular disease history with prior event documentation (for the CV-risk indication), or the pediatric BMI percentile (for the pediatric indication)
- Prior weight-management or lifestyle-intervention history

- The titration plan: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and 2.4 mg maintenance from week 17 onward (with the option to maintain 1.7 mg in patients who cannot tolerate 2.4 mg)
- The monitoring plan: thyroid C-cell tumor symptoms (neck mass, dysphagia, dyspnea, persistent hoarseness), acute pancreatitis, gallbladder disease, acute kidney injury related to dehydration from GI losses, retinopathy progression in patients with T2D, increased resting heart rate, hypersensitivity reactions, and suicidal behavior and ideation as a class-labeled concern
- The contraindications acknowledgement: personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (boxed warning)
- The SFDA pharmacovigilance commitment for the full course of therapy

Public-sector physicians at KFSH&RC, KAMC, MNGHA, KSUMC, and Ministry of Health hospitals hold full signing authority. Private-sector physicians at HMG, Saudi German, Fakeeh, and Dallah sign under their institutional license.

Common questions about Wegovy in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Wegovy? Each insurer assesses case by case. Weight-management coverage varies more than chronic-disease coverage. Some plans exclude obesity therapies, others reimburse partially when BMI and comorbidity thresholds are documented. We do not promise coverage. We supply the documentation set that lets your insurer assess.

How do I know the Wegovy I receive is authentic? Reserve Meds sources only from US authorised distributors operating under the Drug Supply Chain Security Act (DSCSA). Every shipment carries a chain-of-custody dossier from the manufacturer release through US-side handling to international transit to your Saudi receiving pharmacy. Temperature data loggers travel with the shipment. This is the central authenticity proposition relative to regional gray-market alternatives.

Can my child receive Wegovy? Wegovy is approved for pediatric patients 12 years and older with BMI at or above the 95th percentile for age and sex. The pediatric titration schedule is identical to the adult schedule. The treating physician's letter must document the pediatric BMI percentile and the adolescent's clinical course.

What about the 7.2 mg high-dose pen? The 7.2 mg single-injection maintenance pen has been approved by the UK MHRA and the European Commission in late 2025 and early 2026. US availability of the 7.2 mg presentation should be confirmed against the current US FDA label at the time of intake. Reserve Meds sources only US-label presentations.

What is the safety profile? Wegovy carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Most common adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain. Serious adverse events include acute pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity reactions, and a class-labeled concern about suicidal behavior and ideation.

Is the medicine self-administered at home? Yes, after the receiving SFDA-licensed pharmacy has dispensed the pen to you. Wegovy is administered subcutaneously once weekly into the

abdomen, thigh, or upper arm. The receiving pharmacy provides injection training or refers to the manufacturer's instructions.

Where Reserve Meds fits in Wegovy cases

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace SFDA, and do not replace the dispensing pharmacy. For Wegovy specifically we orchestrate the US-side sourcing through an authorised distributor with DSCSA traceability (the authenticity differentiator), the regulatory documentation kit your physician needs (eligibility letter template, titration reference, monitoring plan summary, SFDA pharmacovigilance reference), validated cold-chain logistics with continuous temperature logging and 28-day room-temperature slack management, and a single named coordinator who carries the case through recurring quarterly fills. Common Saudi buyer profiles include the executive-tier patient managing metabolic comorbidities, the family coordinating supply for a parent or spouse, and the post-bariatric patient using GLP-1 maintenance therapy.

Next step

If your treating physician has documented your eligibility and authentic, chain-of-custody supply is what you want, the named-patient pathway through SFDA is the route. Join the waitlist below and we will confirm eligibility within 24 to 48 hours and route the documentation kit to your physician.

Reserved for you.

Review & oversight. Content on this page is reviewed by Reserve Meds's clinical and regulatory team. A US-licensed pharmacist reviews every prescription before dispensing. Regulatory posture is informational, not legal advice; case-specific questions route to retained outside counsel. Review methodology ›
Last medically reviewed: 2026-05-12.